Cellectis S.a. has released a press release.
Cellectis Reports Financial Results for the Second Quarter 2026
Earlier from Cellectis
- Cellectis to Report Second Quarter Financial Results on August 6, 2026
- Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
- Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
- Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL